CRS-207 + Epacadostat + Pembrolizumab
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer
Trial Timeline
Mar 8, 2016 → May 8, 2018
NCT ID
NCT02575807About CRS-207 + Epacadostat + Pembrolizumab
CRS-207 + Epacadostat + Pembrolizumab is a phase 1/2 stage product being developed by Incyte for Platinum-resistant Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02575807. Target conditions include Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02575807 | Phase 1/2 | Terminated |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer